Kurt A. Schalper

Providence Portland Medical Center — United States

Medicine · Health Sciences

70h-index24.2kcitations603works5.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(338), Immunotherapy and Immune Responses(130), Lung Cancer Treatments and Mutations(72), Immune Cell Function and Interaction(59), Radiomics and Machine Learning in Medical Imaging(55)

Publications602 total

MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer
npj Precision Oncology·2025· 1 citedOpen Access
515 Tumor agnostic spatially defined immune cell gene signatures predict immunotherapy outcomes
Regular and Young Investigator Award Abstracts·2025Open Access
Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer
Nature Genetics·2025· 7 citedOpen Access
OA09.01 Machine Learning Assessment of Pathologic Response in Lung Resections After Neoadjuvant Therapy - IASLC MPR Project
Journal of Thoracic Oncology·2025
High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion properties
Journal for ImmunoTherapy of Cancer·2025· 1 citedOpen Access
TRLS-11 UNCOVERING ANTIGEN-SPECIFICITY OF INTRATUMORAL CD8+ T CELLS IN NON-SMALL CELL LUNG CANCER BRAIN METASTASES
Neuro-Oncology Advances·2025Open Access
spEMO: Leveraging Multi-Modal Foundation Models for Analyzing Spatial Multi-Omic and Histopathology Data
2025Open Access
Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology·2025· 1 cited
The tumor microenvironment of non–small cell lung cancer impairs immune cell function in people with HIV
Journal of Clinical Investigation·2025· 6 citedOpen Access
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy
Journal for ImmunoTherapy of Cancer·2025· 3 citedOpen Access
Clinical features associated with an exceptional response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology·2025
A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors.
Journal of Clinical Oncology·2025
A phase 2 study of the olaparib and AZD6738, an ATM/ATR inhibitor, in isocitrate dehydrogenase (IDH) mutant solid tumors.
Journal of Clinical Oncology·2025
Supplementary Figure 12 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
2025Open Access
Supplementary Table 3 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
2025Open Access
Supplementary Figure 5 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
2025Open Access
Supplementary Figure 6 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
2025Open Access
Figure 5 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
2025Open Access
Supplementary Figure 2 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
2025Open Access
Supplementary Figure 13 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
2025Open Access
page 1 of 31Next →

Frequent Co-authors

David L. Rimm(20), Roy S. Herbst(17), Miguel F. Sanmamed(16), Vamsidhar Velcheti(13), Ignacio Melero(13), Scott Gettinger(10), Lieping Chen(8), José Luis Perez‐Gracia(8), Sarah B. Goldberg(6), María E. Rodríguez-Ruiz(6), Justin F. Gainor(5), Ila Datar(5), Daniel Carvajal‐Hausdorf(5), Katerina Politi(5), Matthew D. Hellmann(4), Jun Wang(4), Joseph McLaughlin(4), Valsamo Anagnostou(4), Jungmin Choi(4), Carlos Alfaro(4)